Higher Efficacy of Urinary Bone Resorption Marker Measurements in Assessing Response to Treatment for Osteoporosis in Postmenopausal Women

Abstract

Osteoporosis has reached epidemic proportions. This situation has stimulated the development of biochemical markers to assist in assessing osteoporotic risk and monitoring treatment effi cacy. Biochemical markers for assessing the level of bone resorption have been developed during the last few decades. One of the most widely used bone resorption markers is cross-linked N-terminal telopeptides (NTX). Measurements of urinary and serum NTX provide indications of the level of bone resorption during osteoporosis treatment. However, it remains unclear whether urinary or serum NTX measurements show better effi cacy for assessing osteoporosis treatment effects during the early phase of treatment. Therefore, the primary aim of the present study was to compare the effi cacies of urinary and serum NTX measurements for assessing the level of bone resorption during the early stage of osteoporosis treatment. We enrolled 43 postmenopausal Japanese women in an open-label randomized placebo-controlled trial. Overall, 21 women in the osteoporosis treatment group and 19 women in the placebo group completed the study. There was a signifi cant reduction in urinary NTX in the treatment group, which was detectable as early as 4 weeks and maintained until 16 weeks, compared with the placebo group. On the other hand, serum NTX did not show a signifi cant reduction in the treatment group compared with the placebo group until 16 weeks. These results indicate that urinary NTX measurements are more sensitive and show higher effi cacy than serum NTX measurements for assessing treatment effect during the early phase of osteoporosis treatment in postmenopausal women.biomarker; NTX; osteoporosis; signal-to-noise ratio; postmenopausal women. Tohoku

Bone turnover markers: understanding their value in clinical trials and clinical practice

“…Serum NTX decreases significantly after antiresorptive therapies, but it is less sensitive than urinary NTX in detecting changes induced by such therapies [15]. The reason for this is unknown, and it is still unclear whether dietary intake of collagen can interfere with serum NTX levels.…”

Metabolomic Profiles Delineate Signature Metabolic Shifts during Estrogen Deficiency-Induced Bone Loss in Rat by GC-TOF/MS

“…Specific biochemical indicators for bone turnover, including bone formation markers (B-ALP; Osteocalcin et al), and bone resorption markers (NTx; Tartrate-resistant acid phosphatase-5b, TRCAP-5b; and Carboxy-terminal collagen crosslinks, CTX etc), might be used as index for disease progression of osteoporosis[4]–[6]. These sensitive and validated biochemical markers can offer an alternative to well-accepted BMD test to monitor disease progression of osteoporosis and therapeutic treatment [7], [8]. The disadvantage of the biochemical markers is that they only reflect the alteration of bone formation or bone resorption, while the incidence of osteoporosis is attributed to the dual outcomes of bone formation and resorption.…”

Estimation of Serum Osteocalcin Levels in Osteoporotic Postmenopausal Iraqi Women with Type 2 Diabetes Mellitus

“…[Mean ± SD] of body mass index [BMI], waist circumference [WC] and fat% for the studied groups are shown in Table (1). The results showed that WC of A group is significantly higher than B and control groups, [P < 0.001], Also WC of B group is significantly higher than control groups, [P < 0.…”

“…Osteoporosis is a systemic disease characterized by low bone mass and micro architectural deterioration of bone tissue, resulting in an increased risk of fracture and has touch rampant proportions [1]. According to WHO, 30% of postmenopausal women and 70% of women aged above 80 are affect by osteoporosis [2].…”